10 Results for "

WHO

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "WHO" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-N2093
CAS No.: 152-93-2
Vicine, an alkaloid glycoside found mainly in fava beans, is toxic in individuals who have a hereditary loss of the enzyme glucose-6-phosphate dehydrogenase and may cause haemolytic anaemia.Vicine is an inactive compound that is hydrolysed by the intestinal microflora to a highly reactive free radical generating compound, the aglycone divicine when Vicine enters the body through food .
loading...
    loading...
Cat. No.: HY-Y0286
CAS No.: 506-87-6
Synonyms: Hartshorn salt, 99%
Ammonium carbonate (Ammonium carbonate), 99% is a solid amino compound that functions as a buffer, pH regulator, pore-forming agent, and electrocatalytic oxidation substrate. Ammonium carbonate, 99% is a GRAS-grade direct food additive with no restricted daily intake specified by FAO/WHO, and it shows no acute skin toxicity, clinical signs of toxicity, or effects on body weight in rats. Ammonium carbonate, 99% undergoes electrocatalytic oxidation in alkaline solutions with a Pt/C catalyst (carbonate adsorption interferes with activity). Ammonium carbonate, 99% can serve as a fuel for low-temperature polymer fuel cells and anion exchange membrane fuel cells (with performance superior to pure ammonia), and can also form pores in the carrier-free Pt cathode catalyst layer after low-temperature decomposition, thereby enhancing catalyst activity under low-humidity conditions and the performance of proton exchange membrane fuel cells .
loading...
    loading...
Cat. No.: HY-124187
CAS No.: 493015-74-0
Purity:  ≥98.0%
Synonyms: Ethyl pinolenate
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.
loading...
    loading...
Cat. No.: HY-126830
CAS No.: 1286279-90-0
Target:  

Antifolate Apoptosis

Research Areas:  

Cancer

Antifolate C2 is an anti-folate compound that has inhibitory effects on the proliferation of non-squamous non-small cell lung cancer (NS-NSCLC). Antifolate C2 achieves tumor selectivity by targeting proton-coupled folate transporter (PCFT), which is more selective to PCFT than the commonly used anti-folate drug Pemetrexed (HY-10820). Antifolate C2 blocks the biosynthesis of deoxypurine nucleotides by inhibiting glycinamide ribonucleotide formyltransferase (GARFTase), ultimately inhibiting the proliferation of tumor cells. Antifolate C2 can be used in studies of NS-NSCLC, especially in patients who do not respond well to Pemetrexed .
loading...
    loading...
Cat. No.: HY-147253A
Synonyms: NS 089 sodium; NCNP 02 sodium
Target:  

DNA/RNA Synthesis

Research Areas:  

Neurological Disease

Brogidirsen (NS 089; NCNP 02) sodium is a a dual-targeting antisense oligonucleotide. Brogidirsen sodium can induce dystrophin protein experession. Brogidirsen sodium can be used for the research of Duchenne muscular dystrophy .
loading...
    loading...
Cat. No.: HY-B1116A
CAS No.: 54-49-9
Synonyms: (-)-Metaraminol; (-)-erythro-Metaraminol; (-)-m-Hydroxynorephedrine
Target:  

Adrenergic Receptor

Research Areas:  

Neurological Disease

Metaraminol ((-)-Metaraminol) is a sympathomimetic compound with activity that acts primarily at alpha-1 adrenergic receptors. Metaraminol is used to inhibit hypotension due to vasodilation, particularly in critically ill patients who do not respond well to volume resuscitation. Metaraminol may also be used as an adjunct to help improve cardiac contractility. The use of metaraminol may be supported by less evidence, but its effectiveness in specific situations remains of interest .
loading...
    loading...
Cat. No.: HY-14915
CAS No.: 194785-19-8
Target:  

Adrenergic Receptor

Research Areas:  

Endocrinology

Bedoradrine is a highly selective β2-adrenergic agonist with activity in suppressing asthma and chronic obstructive pulmonary disease (COPD). Bedoradrine is administered by intravenous infusion and is specifically indicated for the suppression of acute asthma attacks. Bedoradrine has shown good safety and preliminary efficacy in clinical trials, especially in patients with stable moderate to severe asthma. The results of Bedoradrine studies have shown that it can provide clinical benefits without increasing clinical risks, especially for patients who are unable to use inhalation or nebulization suppression .
loading...
    loading...
Cat. No.: HY-16731
CAS No.: 676479-06-4
Synonyms: EVT 302; RG1577; RO4602522
Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity .
loading...
    loading...
Cat. No.: HY-L142
156 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 156 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.: HY-L073
396 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 396 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.